![]() |
市场调查报告书
商品编码
1753953
2025 年至 2033 年腹膜透析市场报告(依治疗类型(持续性门诊腹膜透析、自动腹膜透析)、产品、最终用户和地区)Peritoneal Dialysis Market Report by Treatment Type (Continuous Ambulatory Peritoneal Dialysis, Automated Peritoneal Dialysis ), Product, End User, and Region 2025-2033 |
2024年,全球腹膜透析市场规模达180亿美元。展望未来, IMARC Group预计到2033年,市场规模将达到265亿美元,2025-2033年期间的复合年增长率(CAGR)为4.16%。全球透析中心数量的不断增加、政府推动肾臟疾病管理的倡议不断增多、持续性非卧床腹膜透析(CAPD)的日益普及以及发展中国家医疗基础设施的不断扩大,共同推动着市场的发展。目前,受优惠的报销政策和老龄人口不断增长的推动,北美占据着最大的腹膜透析市场份额。
腹膜透析 (PD) 是一种肾衰竭治疗程序,透过手术将一根柔软的塑胶管或导管置入腹腔内壁或腹部。置入后,无菌清洁液会经由导管输送,帮助过滤体内血液,清除废物。一段时间后,液体和过滤后的有害成分会从腹腔排出并被丢弃。 PD 分为持续性非卧床腹膜透析和持续性循环腹膜透析 (CCPD)。这些方法治疗灵活,减少了前往透析中心的次数,并能获得更好的临床疗效,从而减少药物用量和饮食限制。此外,PD 可以在家中进行,无需针头;因此,医院和医疗中心经常使用 PD 来治疗肾衰竭。
末期肾病(ESRD)盛行率不断上升
末期肾病 (ESRD) 盛行率的不断上升是推动全球腹膜透析市场成长的关键因素,因为 ESRD 患者需要透析或肾臟移植才能存活,而腹膜透析因其便利性和居家性质而成为首选治疗方法。根据美国肾臟资料系统 (USRS) 的数据,2015 年新增 ESRD 诊断病例 124,411 例,且每年新增病例数约为 20,000 例。随着全球 ESRD 病例数持续上升,对有效且便利的透析方案(包括腹膜透析)的需求也随之成长。透析技术的进步进一步推动了这一趋势,有助于满足日益增长的 ESRD 人群日益增长的医疗保健需求。
糖尿病和高血压发生率不断上升
糖尿病和高血压发生率的上升是推动腹膜透析市场份额扩大的重要因素,因为这些疾病是慢性肾病 (CKD) 和终末期肾病 (ESRD) 的主要原因。糖尿病和高血压都会损害血管并逐渐降低肾功能,最终需要透析或肾臟移植才能存活。随着全球糖尿病和高血压盛行率的上升,尤其是在老年人口中,肾衰竭病例也相应增加。因此,对包括腹膜透析在内的各种透析治疗的需求正在增加,从而推动了腹膜透析市场的成长。这种透析为患者提供了一种方便的家庭解决方案,使其成为治疗与这些常见健康状况相关的肾衰竭的首选。
医疗支出不断上涨
不断增长的医疗保健支出也在推动市场发展,同时也使人们能够更广泛地获得先进的透析治疗。随着全球(尤其是已开发国家)医疗保健支出的增加,越来越多的资金被分配用于管理肾衰竭等慢性疾病。这有利于改善基础设施,培养训练有素的医疗专业人员,并让更多人获得尖端的腹膜透析技术。此外,根据腹膜透析市场分析报告,医疗保健预算的增加促进了居家治疗的普及,与中心血液透析相比,居家治疗更具成本效益,也更加便利。全球许多国家的政府计画和保险政策也更有利于支持长期透析护理,从而减轻了患者的经济负担,并推动了对作为综合医疗保健体系一部分的、可及的高品质腹膜透析解决方案的需求。
The global peritoneal dialysis market size reached USD 18.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 26.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4.16% during 2025-2033. The market is being driven by the rising number of dialysis centers worldwide, the increasing government initiatives to promote kidney disease management, the growing adoption of continuous ambulatory peritoneal dialysis (CAPD), and the expanding healthcare infrastructure in developing countries. At present, North America holds the largest peritoneal dialysis market share, driven by favorable reimbursement policies and the rising geriatric population.
Peritoneal dialysis (PD) represents a type of kidney failure treatment procedure wherein a soft plastic tube or catheter is placed in the abdominal lining or belly through surgery. Once it is positioned, a sterile cleansing fluid is transmitted by the duct that helps filter the blood inside an individual's body by removing waste products. After a period of time, the liquid and filtered unwanted components flow out of the abdomen and are discarded. PD is differentiated into continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis (CCPD). These approaches offer treatment flexibility, reduce the need to visit dialysis centers, and provide better clinical outcomes, resulting in lesser medications and fewer food restrictions. Apart from this, it can be carried out at home and is needle-free; thus, PD is used by hospitals and healthcare centers to treat kidney failures.
Growing prevalence of end-stage renal disease (ESRD)
The growing prevalence of end-stage renal disease (ESRD) is a key factor driving the global peritoneal dialysis market growth as ESRD patients require dialysis or kidney transplantation to survive, with peritoneal dialysis emerging as a preferred treatment due to its convenience and home-based nature. According to the United States Renal Data System, there were 124,411 new ESRD diagnoses in 2015, with the disease increasing at about 20,000 cases per year. As the number of ESRD cases continues to rise globally, the demand for effective and accessible dialysis options, including peritoneal dialysis, increases. This trend is further supported by advancements in dialysis technologies, helping to meet the growing healthcare needs of the expanding ESRD population.
Increasing incidences of diabetes and hypertension
The rising incidences of diabetes and hypertension are significant drivers contributing to the augmenting peritoneal dialysis market share, as these conditions are the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Both diabetes and hypertension damage blood vessels and reduce kidney function over time, ultimately requiring dialysis or kidney transplantation for survival. With the global prevalence of diabetes and hypertension on the rise, particularly in aging population, there has been a corresponding increase in kidney failure cases. As a result, the demand for various dialysis treatments, including peritoneal dialysis, is escalating, thereby impelling the peritoneal dialysis market growth. This type of dialysis offers a convenient, home-based solution for patients, making it a preferred choice for managing kidney failure linked to these common health conditions.
Rising healthcare expenditures
Rising healthcare expenditures are also driving the market while enabling broader access to advanced dialysis treatments. As healthcare spending increases globally, especially in developed countries, more funds are allocated to managing chronic diseases like kidney failure. This allows for improved infrastructure, better-trained medical professionals, and access to cutting-edge peritoneal dialysis technologies. Additionally, according to the peritoneal dialysis market analysis report, increased healthcare budgets facilitate the adoption of home-based treatments, which can be more cost-effective and convenient compared to in-center hemodialysis. Government programs and insurance policies are also better positioned across numerous countries across the globe to support long-term dialysis care, thus easing the financial burden on patients and driving the demand for accessible, quality peritoneal dialysis solutions as part of comprehensive healthcare systems.